What Happened this Week? Human Embryos Back on the Bench, Stem Cells in your Heart and New Antibiotics

Monday: Nabriva Therapeutics launched its $100M IPO on the NASDAQ to develop new antibiotics

Tuesday: the Francis Crick Institute announced its application to conduct new research on human embryos

Wednesday: Israeli NovoCure announced an IPO on NASDAQ with a target of €170M

Thursday: Belgian TiGenix NV released the phase I results of their cardiac stem-cell therapy

Friday: in a successful phase III trial, the Amgen biosimilar showed full-efficacy equivalent to Roche’s Avastin

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.

We use cookies to give you the best experience and for advertising purposes. By accepting, you support our independent media and its' freely accessible content.